President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
"The plan offered by Senator Breaux and his colleagues included some very strong elements, which should be seriously considered by Congress," Clinton said. "However, I believe their approach falls short in several respects."
Among those shortcomings, according to Clinton, are the lack of a prescription drug benefit, the potential to raise premiums for those in the traditional Medicare program, a raise in the age of eligibility for Medicare (from 65 to 67) and no solid commitment to financing a Medicare trust fund.
Clinton said his advisors will draft a plan for Congress to consider. Almost certainly, Clinton's plan will earmark 15% of the federal surplus to a trust fund for Medicare and include a prescription drug benefit. It is unclear, however, whether his plan will include a universal Medicare prescription drug benefit, which some industry experts have predicted could cost the nation more than $30 billion.
Despite Clinton's lack of support, Breaux indicated that he might still introduce Medicare reform legislation for debate this fall. PR
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
March 14th 2025New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.